Financial Data and Key Metrics Changes - Product sales decreased by $15.8 million or 10.9% in 2024 compared to 2023, primarily due to a decrease in unit volume shipped in direct sales and inventory finance sales categories [7] - Net revenue per product sold increased by 1.9% in 2024 compared to 2023, driven by a moderate increase in unit prices [8] - Net income increased by 13.2% to $61.6 million in 2024 compared to 2023, with basic earnings per share increasing by $0.32 or 14.3% [14] - Cash increased to approximately $1.1 million as of December 31, 2024, compared to $0.7 million as of December 31, 2023 [14] - Book value per basic share outstanding increased by 13.9% to $20.40 as of December 31, 2024 [15] Business Line Data and Key Metrics Changes - Consumer MHP and dealer loans interest income increased by $3.8 million or 10.1% from 2023 to 2024 due to growth in loan portfolios [8] - Other revenue increased by $7.0 million or 106.3% from 2023 to 2024, primarily due to $8.9 million in land sales [10] - Gross profit margin for product sales was 30.4% in 2024, down from 31.3% in 2023 [12] - Selling, general and administrative expenses decreased by $1.1 million or 4.4% in 2024 compared to 2023 [13] Market Data and Key Metrics Changes - The average price for a new single-family home in 2023 was $511,000, compared to a manufactured home price of $123,000 [18] - Legacy's average selling price in 2024 was approximately $61,000 per unit, up from $60,000 in 2023 [20] - Retail finance fundings in Q1 2025 are tracking well ahead of the 8% growth seen in 2024 [22] Company Strategy and Development Direction - The company continues to focus on the long-term fundamentals of manufactured housing, emphasizing high-quality, affordable homes and financing solutions [17] - Plans for 2025 include focusing on sales, particularly park sales in Texas and dealer sales in the Southeast, while streamlining product offerings and processes [28] - The company is in a strong net cash position and plans to repurchase shares aggressively if stock prices decline [29] Management's Comments on Operating Environment and Future Outlook - Management acknowledges significant market uncertainties, including politics, tariffs, and recession risks, but remains committed to closely managing the business [16] - The affordable housing crisis is highlighted as a critical issue, with the manufactured housing industry seen as a necessary part of the solution [21] - Management expects production rates to improve as they ramp up production at Texas facilities, with a focus on building backlog [52] Other Important Information - The company sold a mobile home park as part of a settlement agreement, resulting in a meaningful gain [26] - The company is actively developing properties in Austin, with plans to sell lots in Phase 1 of a development project [27] Q&A Session Summary Question: Can you provide more details on land sales during the quarter? - The significant sale was a mobile home park from a settlement agreement in Beaumont, Texas, with other land monetized throughout the year [32] Question: Did you purchase any land in Q4 in Texas? - The company did not purchase land but is focused on foreclosing on development loans secured by land [35] Question: What are the concerns regarding delinquencies and the ability to recover loans? - Past due balances have increased slightly, but recovery remains strong due to home price increases and down payment requirements [38] Question: How might changing immigration policies impact customers and labor? - The company has not seen a material change in business from immigration policies, as they have stable borrowers [45] Question: Are there any expectations for increasing SG&A expenses in 2025? - Management does not foresee any material changes in SG&A expenses [47]

US Energy (NASDAQ:USEG) Q4 2024 Earnings Conference Call March 13, 2025 9:00 AM ET Company Participants Mason McGuire ??? Vice President-Finance and Strategy Ryan Smith ??? Chief Executive Officer Mark Zajac ??? Chief Financial Officer Conference Call Participants Jesse Sobelson ??? D. Boral Capital Charles Meade ??? Johnson Rice Tom Kerr ??? Zacks Small Cap Research Operator Greetings and welcome to U.S. Energy Corporation Fourth Quarter and Year End 2024 Results Conference Call. At this time, all particip ...

Financial Data and Key Metrics Changes - The company ended 2024 with cash and cash equivalents of $23.3 million, up from $9.6 million as of December 31, 2023 [20] - The net loss for the full year ended December 31, 2024, was $44.6 million or $1.22 per basic share, compared to a net loss of $42.8 million or $3.50 per basic and fully diluted share during 2023 [23] Business Line Data and Key Metrics Changes - Research and development expenses for the full year 2024 were approximately $26.1 million, down from $27.3 million in the prior year, primarily due to timing of expenditures for the WM Phase 2 study [20][21] - Selling, general and administrative expenses for the full year 2024 were $25.6 million, compared to $11.7 million in the prior year, driven by pre-commercialization initiatives [21][22] Market Data and Key Metrics Changes - The company is focused on the relapsed/refractory Waldenstrom's macroglobulinemia (WM) market, with iopofosine showing a significant clinical benefit rate of 98.2% and an overall response rate of 83.6% in the CLOVER-WaM study [9][10] - The company is also advancing its solid tumor-focused radioisotope programs, including alpha emitters for pancreatic cancer and Auger emitters for triple-negative breast cancer [15] Company Strategy and Development Direction - The company aims to address its NASDAQ status and future funding through non-dilutive funding opportunities and collaborations [8][15] - A strategic restructuring was implemented to reduce headcount by approximately 60%, expected to save about $7.5 million annually [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential value of iopofosine for patients with relapsed/refractory WM, despite regulatory setbacks delaying the NDA submission [11][12] - The company anticipates rapid enrollment in the upcoming Phase 3 study for iopofosine, with a clear regulatory pathway established with the FDA [28][47] Other Important Information - The company is preparing for Phase 1 studies for both CLR 121225 and CLR 121125 in 2025, targeting pancreatic cancer and triple-negative breast cancer respectively [49][42] - The company is exploring various deal types for licensing iopofosine, including global partnerships and regional rights [81][84] Q&A Session Summary Question: Does the NDA acceptance require data from the confirmatory study or just the CLOVER study? - The accelerated approval will require data from the additional study as well [56] Question: What is the timeline for patients to achieve and be evaluated for an MRR response? - Enrollment is expected to take approximately 24 months, with major response rate outcomes assessed about one month after enrollment [62] Question: What would be the comparator in the study? - The study will have an investigator choice design with two comparators, one being rituximab monotherapy [66][67] Question: Does the cash runway include costs for IND filings for CLR 121225 and 125? - Yes, the runway includes costs for IND filings, estimated to be relatively modest [71] Question: Why is pancreatic cancer chosen for CLR 121225? - The choice is based on significant market need and strong preclinical efficacy signals [90]

Financial Data and Key Metrics Changes - Revenue for fiscal year 2024 was $8.8 million, essentially flat compared to fiscal year 2023 revenue of $8.8 million [30] - Bookings for fiscal year 2024 reached a record $23.9 million, an increase of 128% from fiscal year 2023 bookings of $10.5 million [30] - GAAP gross profit for fiscal year 2024 was $5.6 million, a 20% increase from fiscal year 2023 gross profit of $4.6 million [31] - Net loss for fiscal year 2024 was $143.9 million, compared to a net loss of $82.7 million in fiscal year 2023 [32] - Adjusted EBITDA loss for fiscal year 2024 was $56 million, an increase of 3% from the adjusted EBITDA loss of $54.3 million in fiscal year 2023 [33] Business Line Data and Key Metrics Changes - The fourth quarter revenue totaled $2.3 million, a decrease of 21% from the fourth quarter of fiscal year 2023 revenue of $2.9 million [34] - Bookings for the fourth quarter were a record $18.3 million, an increase of over 500% compared to the fourth quarter of fiscal year 2023 bookings of $3 million [34] - Non-GAAP gross profit for the fourth quarter was $1.7 million, a decrease of 28% from the fourth quarter of fiscal year 2023 non-GAAP gross profit of $2.3 million [34] Market Data and Key Metrics Changes - D-Wave had a total of 135 customers in fiscal year 2024, compared to 133 customers in fiscal year 2023 [30] - The customer base included 59 research institution and government customers in 2024, up from 55 in fiscal year 2023 [30] - The number of commercial customers was 76 in fiscal year 2024, down from 78 in fiscal year 2023 [30] Company Strategy and Development Direction - D-Wave aims to be the first pure play quantum company to reach profitability with less cash invested than competitors [10] - The company is focusing on a quantum compute as a service model for the majority of its commercial customers while also pursuing system sales [18] - D-Wave is developing a sixth generation annealing quantum computer, Advantage 2, which is expected to deliver significant performance gains [15] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of the recent demonstration of quantum supremacy as a significant milestone for the quantum industry [57] - The company expects to see increased interest in system sales and believes that the recent achievements will positively impact customer engagement [49] - Management anticipates fiscal year 2025 Q1 revenue to exceed $10 million, driven by the sale of an Advantage annealing quantum computer [39] Other Important Information - D-Wave's cash balance exceeded $300 million, which is believed to be sufficient to reach sustained profitability [10] - The company completed two separate ATM programs in the fourth quarter that brought in a total of $175 million in gross proceeds [25] - D-Wave announced a quantum uplift program to attract organizations dissatisfied with competitors' quantum systems [22] Q&A Session Summary Question: Insights on Advantage 2's impact on existing commercial engagements - Management confirmed that Advantage 2's capabilities will enhance performance for existing customers and attract new ones [44] Question: Future system sales and revenue expectations - Management indicated ongoing discussions with three other institutions for potential system sales, but did not provide specific revenue guidance [50] Question: Impact of recent publications on industry perception - Management noted that the recent achievement has positively influenced both the academic community and commercial entities, despite some resistance [56] Question: Breakdown of revenue recognition from the Jülich system sale - Management clarified that revenue from the Jülich system sale will be recognized in the first quarter following installation and acceptance [105] Question: Future revenue models for system sales - Management stated that future deals will be tailored to customer needs, affecting the structure of revenue recognition [75] Question: Potential for scaling and R&D acceleration - Management expressed interest in accelerating R&D efforts, particularly in scaling quantum systems and exploring gate model opportunities [86]

Financial Data and Key Metrics Changes - In Q4 2024, the company achieved a net income of $22 million and EBITDA of $67 million, marking a strong quarter with the highest production of 57,364 ounces for the year [5][10] - Gold revenue for Q4 was $148 million, a 13% increase compared to Q3, driven by a higher realized gold price of $2,642 per ounce and increased sales volumes [14] - For the full year 2024, adjusted EBITDA totaled $163.1 million and adjusted earnings were $55.9 million, or $0.35 per share [15][19] Business Line Data and Key Metrics Changes - Segovia produced 188,000 ounces of gold, while the Marmato Upper Mine contributed 23,000 ounces, totaling 211,000 ounces for the year [10] - In Q4, Segovia's production increased by 8% to 51,477 ounces, with a 7% rise in average gold grade processed [11] - The all-in sustaining costs (AISC) at Segovia reduced by 4% to $1,485 per ounce in Q4, despite an 8% increase in realized gold costs [11] Market Data and Key Metrics Changes - The company expects annual production from Segovia to reach between 210,000 to 250,000 ounces in 2025, with a target of 300,000 ounces from 2026 onwards [6][32] - The AISC margin at Segovia reached a three-year high of $58 million in Q4, a 32% increase from the previous quarter [17][40] Company Strategy and Development Direction - The company is focused on expanding its processing facilities at Segovia and Marmato to increase production capacity, targeting over 500,000 ounces of gold annually once expansions are fully operational [8][30] - The Segovia processing plant expansion is expected to ramp up to 300 tonnes per day by the end of 2025, with a total cost of $15 million for the project [23][28] - The Marmato Lower Mine construction is progressing, with plans to expand processing capacity from 4,000 tonnes per day to 5,000 tonnes per day, aiming for an annual production of 200,000 ounces [25][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position, with a year-end cash balance of $253 million, positioning it well for growth [8][40] - The company remains focused on operational efficiencies and cost control, despite the strong gold price environment [17][34] Other Important Information - The company generated a cash inflow of $164 million in Q4, including $136 million from refinancing bonds and $40 million from a precious metals stream [20] - The total estimated cost to complete the Marmato Lower Mine construction is $365 million, with a net construction cost to the company of $208 million after considering remaining stream funding [28][29] Q&A Session Summary Question: How long has the company been considering the expansion and why now? - Management indicated that the expansion has been under consideration for over a year, with the decision to reshape plans based on insights gained from the Upper Mine [45][46] Question: What is the expected capital expenditure for this year versus next year for the expansion? - The company forecasts approximately $260 million in capital expenditure for this year, with an additional $50 million possible depending on spending [48]

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was HK$4.4 billion, an increase of 87% from HK$2.4 billion in Q4 2023. Full-year revenue grew to HK$13.6 billion, up 36% year-over-year [21][30] - Brokerage commission and handling charge income reached HK$2.1 billion, a 128% year-over-year increase and a 35% quarter-over-quarter increase [21][22] - Net income increased by 113% year-over-year and 42% quarter-over-quarter to HK$1.9 billion, with a net income margin expanding to 42.2% [30] Business Line Data and Key Metrics Changes - In Q4, the number of new paying clients reached 215,000, bringing total paying clients to over 2.4 million, a 41% year-over-year increase [7][8] - Total trading volume jumped by 202% year-over-year and 52% quarter-over-quarter to HK$2.89 trillion, with U.S. stock trading volume growing by 36% sequentially [15][16] - Total client assets in wealth management increased by 93% year-over-year and 14% quarter-over-quarter to HK$111 billion [17] Market Data and Key Metrics Changes - The Hong Kong market was the top growth driver for new paying clients, with a significant rebound in trading velocity starting from September [8][16] - Singapore recorded a 19% quarter-over-quarter growth in total client assets, marking the 10th consecutive quarter of growth [14] - In Japan, new paying clients grew double-digit quarter-over-quarter, driven by a bullish U.S. market backdrop [10] Company Strategy and Development Direction - The company aims to add 800,000 new paying clients in 2025, focusing on existing markets without entering new ones [7][37] - A strong emphasis on enhancing product offerings, including the launch of crypto trading in the U.S. and expanding wealth management services [46][72] - The company is leveraging AI to improve operational efficiency and client-facing capabilities, enhancing user experience [53][56] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about client acquisition growth in existing markets, particularly in Hong Kong and Singapore, due to favorable market conditions [37][108] - The company anticipates continued robust net asset inflow in 2025, despite potential market volatility [107][108] - Management highlighted the importance of maintaining a balance between user experience and compliance in AI applications [56] Other Important Information - The company underwrote 40 Hong Kong IPOs in 2024, ranking first among all brokers for the third consecutive year [19] - The introduction of the new digital IPO settlement platform, FINI, is expected to enhance retail participation in the market [20] Q&A Session Summary Question: Guidance for new paying clients in 2025 - Management clarified that the guidance of 800,000 new paying clients does not include new markets, focusing on existing markets with strong growth potential [37] Question: Client acquisition cost (CAC) increase - Management targeted a CAC of HK$2,500 to HK$3,000 for 2025, attributing the increase to brand equity investments [38] Question: Current trading volume and market performance - Management noted robust trading opportunities in both Hong Kong and U.S. markets, forecasting higher net asset inflows and trading volumes [44] Question: Product pipeline for equity derivatives and crypto - Management confirmed a rich product pipeline for overseas markets, including crypto trading planned for the U.S. [46] Question: Impact of U.S. stock market correction on trading volume - Despite setbacks in the U.S. stock market, management observed increased trading activity due to market volatility [61] Question: Breakdown of interest income - Approximately 40% to 45% of interest income was derived from idle cash deposits, with the remainder from margin financing and security lending [99] Question: Share buyback program and capital return plans - Management has not utilized the share repurchase program yet, focusing on growth opportunities in new markets [92] Question: Derivatives trading percentage in total volume - Derivatives accounted for roughly one-third of total trading commissions in Q4, with no significant changes expected in Q1 [97]

Financial Data and Key Metrics Changes - Seres reported a net loss from continuing operations of $15.7 million for Q4 2024, compared to a net loss of $34.7 million for the same period in 2023, indicating a significant improvement [49] - For the full year 2024, the net loss from continuing operations was $125.8 million, down from $190.1 million in 2023, primarily due to lower operating expenses of approximately $74 million [49] - Research and development (R&D) expenses for Q4 2024 were $12.8 million, down from $23 million in Q4 2023, and for the full year, R&D expenses were $64.6 million compared to $117.6 million in 2023 [51] - General and administrative (G&A) expenses for Q4 2024 were $12.5 million, down from $14 million in Q4 2023, and for the full year, G&A expenses were $53.2 million compared to $77.5 million in 2023 [52] Business Line Data and Key Metrics Changes - The company has made substantial progress in advancing its lead program SER-155, which aims to prevent bloodstream infections in allo-HSCT recipients [8][12] - SER-155 showed a clinically meaningful 77% relative risk reduction in bloodstream infection rates in a Phase 1b study [10][23] - The FDA granted breakthrough therapy designation to SER-155, indicating significant progress in its development [13][58] Market Data and Key Metrics Changes - The commercial opportunity in allo-HSCT alone is considered sizable, with potential for indication expansion to adjacent patient populations [39][40] - There are approximately 9,300 allo-HSCT procedures conducted annually in the US, with an estimated 20,000 procedures in Europe [43] Company Strategy and Development Direction - The company is focused on SER-155 and exploring partnerships to support its development and maximize its potential [17][61] - SER-155 is positioned to address a significant unmet need in preventing bacterial bloodstream infections, with plans to extend its application to other medically vulnerable groups [40][61] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress made with SER-155 and the constructive feedback received from the FDA [58] - The company is preparing for the next study of SER-155 and expects to submit a draft study protocol to the FDA in the second quarter [21][22] Other Important Information - The company is now debt-free following the VOWST transaction, which provided $155 million at closing [46][47] - The cash position as of December 31, 2024, was $30.8 million, with expectations to fund operations into the first quarter of 2026 [55] Q&A Session Summary Question: Feedback from the FDA regarding manufacturing and patient enrollment - Management indicated that they received comprehensive feedback from the FDA and are in the process of refining the clinical study protocol [67][70] - The population for the next study is considered appropriate, with plans to manage variability through stratification [72] Question: Recent FDA feedback relative to expectations and Phase 2/3 study differences - Management found the FDA feedback constructive and believes more data is needed for the next study [80][84] - A Phase 2/3 study would require pre-specification and locking of certain items, which could take more time [83] Question: Safety database considerations based on VOWST experience - Management noted that the FDA has a minimum threshold of 300 patients for safety data, but discussions will evolve as more data is generated [92] Question: Potential size of the next study and additional efficacy endpoints - Management indicated that a standalone Phase 2 could provide meaningful data quickly, with various endpoints being considered, including GvHD rates [100][102]

Financial Data and Key Metrics Changes - For 2024, the company generated $150 million in service revenue, a 10% increase over 2023, driven by growth in both business segments [8][10] - Adjusted EBITDA for 2024 was $17.4 million, representing an $18.3 million improvement over 2023 [8][10] - The company reduced its debt by over $60 million, from $233 million to $172.5 million, significantly strengthening its balance sheet [12][14] Business Line Data and Key Metrics Changes - The Servicer and Real Estate segment reported service revenue of $120 million, an 11% increase from 2023, with adjusted EBITDA of $42.1 million, up $5 million or 14% [17][18] - The Origination segment achieved service revenue of $30.4 million, a 6% increase from 2023, with adjusted EBITDA improving by $5.4 million to $2.5 million [20][21] - The Corporate segment's adjusted EBITDA loss decreased by $7.9 million or 22% to $27.2 million, reflecting efficiency initiatives [22] Market Data and Key Metrics Changes - Foreclosure starts in 2024 were 35% lower than 2019 levels, and foreclosure sales were 53% lower than 2019 levels, indicating a challenging market environment [23] - The origination market faced difficulties, with 2024 mortgage origination volume 35% lower than 2019 levels, primarily due to higher interest rates [24] Company Strategy and Development Direction - The company aims to diversify its revenue base and ramp up business won while maintaining cost discipline and significantly reducing corporate interest expense [28] - Focus areas for growth include the renovation business, Lenders One solutions, and expanding the Hubzu platform to include commercial auctions [38][40] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2025, forecasting service revenue between $165 million and $185 million, representing 16% annual growth, and adjusted EBITDA of $18 million to $23 million [26][27] - The company anticipates positive operating cash flow for the first time since 2019, driven by sales wins and improved margins [26][27] Other Important Information - The company completed a significant transaction with lenders in February 2025, which is expected to be accretive to pre-transaction shareholders in the medium to long term [16][28] - The interest rate on the new term loan and super senior credit facility is SOFR plus 650 basis points, resulting in a substantial reduction in annual cash interest costs [12][13] Q&A Session Summary Question: Can you comment on the nature of some of the wins you've had across originations and servicing? - Management highlighted successful initiatives in the construction renovation and Lenders One businesses, with both achieving over $1 million a month in revenue [34][35] Question: How are things trending thus far in 2025? - Management reported a strong start to 2025, with January revenue and EBITDA results aligning with plans, and February revenue also on target [42][43] Question: When do you think the increase in foreclosure starts will be reflected in results? - Management noted that while they are being conservative in forecasting, anecdotal evidence suggests clients expect an increase in foreclosure starts [48][50] Question: Are there other agencies implementing unfriendly creditor policies that might impact the business? - Management mentioned the FHA's new programs and indicated that borrowers are continuing to default on modified loans, which could lead to increased business in the future [54][56] Question: Will there be a sizable gain in Q1 that could reduce the negative equity position on the balance sheet? - Management confirmed that interest expense will decrease significantly, and they expect strong revenue and EBITDA results in Q1 [60][62]

Financial Data and Key Metrics Changes - Total fourth quarter revenues reached $83 million, an increase of 11% year-over-year, while full year revenues increased by 18% to $336 million [8] - Net loss improved to $8.6 million or $0.08 per share from $22.5 million last year, with the current loss including a $10.5 million write-down [30] - Consolidated adjusted EBITDA was negative $3.5 million, but would have been $7 million excluding the inventory write-down, marking the best results in four years [30][35] Business Line Data and Key Metrics Changes - Canadian cannabis net sales grew by 10% year-over-year, driven by non-branded and international sales, with international medicinal exports up 127% year-over-year [34] - Fresh produce sales increased by 17% year-over-year to $43.3 million, with adjusted EBITDA positive at $4.1 million compared to negative $600,000 last year [32][33] - U.S. cannabis business saw a sequential revenue increase of 17% to $4.6 million, with a gross margin of 70% and adjusted EBITDA returning to positive territory at $300,000 [37] Market Data and Key Metrics Changes - The Canadian cannabis market remains competitive, with the company holding the 3 market share position overall and being the second fastest growing licensed producer organically during 2024 [12] - International cannabis sales for the year increased to CAD 8.4 million, with strong growth momentum continuing into 2025 [18] - The New Zealand medical cannabis market is forecasted to grow at a compounded annual growth rate of 58% over the next five years [17] Company Strategy and Development Direction - The company is prioritizing profitable sales growth over low-margin volume in Canada, focusing on maintaining a leadership position before expanding into other markets [10] - Plans to move extraction and vape manufacturing in-house are underway, aiming to capture profitable market share with new product offerings [14] - The company is optimistic about the Dutch market, having completed its first harvest and commenced sales, with plans for a Phase 2 cultivation facility to quadruple production capabilities [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's momentum and ability to execute on growth opportunities, despite the inventory impairment in Q4 [15][23] - The company is well-positioned to deliver a successful year of profitable growth in 2025 and beyond, with a focus on international expansion [43] - Management acknowledged the challenges posed by potential tariffs but remains confident in their ability to adapt and manage costs effectively [25][27] Other Important Information - The company paid nearly CAD 100 million in excise taxes in 2024, which is more than double their SG&A expenses, highlighting the significant impact of these taxes on profitability [36] - The company ended Q4 with cash of $24.6 million and a working capital of $53.8 million, maintaining a comfortable net debt level of $15.9 million [40][41] Q&A Session Summary Question: Impact of inventory impairment on revenue - Management clarified that the impairment did not impact revenue as the decision was made to not sell suboptimal products [49][51] Question: Future market share and product allocation - Management indicated that while Canada remains a foundation, they are focusing on high-quality products and will meet domestic demand while also addressing international opportunities [58] Question: Status of licensed producers in the Netherlands - Management confirmed that only seven out of ten licensed producers are operational, with a firm deadline for coffee shops to buy exclusively from licensed producers by April 7 [64][66] Question: Growth expectations for international sales - Management expects to triple international medicinal export sales in 2025, with a focus on existing medical markets, separate from the recreational market in the Netherlands [75] Question: Risk of oversupply in the Canadian market - Management does not foresee a return to oversupply levels seen in previous years, citing limited biomass in the marketplace and steady demand for high-quality products [78][80]

Financial Data and Key Metrics Changes - Fourth quarter revenue was $64.4 million, down from $73.6 million in Q4 2023, reflecting a decline in both segments [17] - Professional segment revenue declined 8.7% year-over-year and 3% sequentially, but grew 2% sequentially on a billing day adjusted basis [17] - Gross profit was $21.5 million in Q4 with a margin of 33.3%, compared to 34.6% in the prior year, attributed to increased competition and economic pressures [19] - Adjusted EBITDA was $1.4 million or 2.2% of revenue, down from $3.4 million or 4.8% in Q3 [20] Business Line Data and Key Metrics Changes - In the Professional segment, monthly IT contract revenue normalized for billing days reached its lowest point in June 2024, but has since stabilized or grown sequentially [12] - The Property Management segment saw a significant restructuring, with revenue trends expected to improve starting mid-2025, despite current challenges in the multifamily housing sector [14][15] - A 23% increase in revenue was driven by territory mapping initiatives in key markets [15] Market Data and Key Metrics Changes - The broader multifamily housing sector is facing challenges due to rising operating expenses and credit issues, impacting the Property Management segment [14] - Increased customer engagement and a 30% rise in signed master service agreements compared to Q4 2023 indicate a growing opportunity pipeline [13] Company Strategy and Development Direction - The company announced a restructuring plan aimed at reducing costs and improving operational performance, expecting cash savings of approximately $7 million to $9 million in 2025 [9] - Investments in technology, partnerships, and people are expected to drive long-term value creation, with a focus on enhancing profitability in 2025 [24] - The company is leveraging AI capabilities through the Arroyo team to address client needs and improve service delivery [40][41] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the second half of 2025, with expectations for improvement in property management revenue trends [32] - The economic and political uncertainties have created a more cautious environment, but management remains committed to providing updates on strategic alternatives [11][25] Other Important Information - The company has been recognized as one of the best places for working parents for five consecutive years [8] - A new lead generation engine launched in Q3 generated $2 million in revenue for the property management team [22] Q&A Session Summary Question: What type of cadence could be expected in terms of seeing restructuring on the SG&A line? - Management indicated that the majority of cuts took place in December and will start showing up in Q1 results, with further reductions throughout the year [28] Question: How is the process going with relocating operations to Arroyo? - Management expressed pride in the Arroyo team's capabilities and ongoing efforts to streamline costs [30] Question: What improvements are expected in the second half of the year for property management? - Management noted hopeful conversations within the National Apartment Association regarding potential improvements [32] Question: How is client feedback on professional services and new logos? - Management reported increased activity in the pipeline and optimism following recent elections, with more scope meetings occurring [35] Question: How will the $7 million to $9 million annual savings be realized? - The majority of cost savings were personnel-related and will be reflected in Q1, with further changes in commission plans expected in Q2 [48] Question: What percentage of the footprint is utilizing territory mapping? - Management confirmed that territory mapping has been launched in key markets like Houston and Atlanta, with plans for further expansion [54]